Companies · Biotechnology
DORAL · Biotechnology
Diligence memoA one-page analyst read on Mel-Mont Medical, Inc. — recommendation, valuation, rhythm, risks.→Mel-Mont Medical, Inc. looks under-valued against its niche peers and is active on financing cadence.
Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.
Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.
No named principal in this company's public records yet — see all operators below.
Explore how these operators interlock with other companies in the operator network.
Mel-Mont Medical, Inc. is one of 4293 Biotechnology companies tracked from DORAL. By capital raised it ranks mid-pack (ahead of 57% of sector peers), and in the long tail by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.
Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 67%.
Round size and date are reported; the stage label is inferred from round size (latest is Series A — a $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.
Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 57% of sector peers (real $). Modeled value above 2% of peers (estimate).
A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #156 of 157.
| Company | Stage | Raised · real | Value · est | vs peer med. |
|---|---|---|---|---|
| Acasti Pharma Inc. | Series A | $23.0M | $58.6M | 3.75× |
| Edesa Biotech, Inc. | Series A | $36.9M | $58.5M | 3.74× |
| 4DMedical Ltd | Series A | $15.0M | $50.7M | 3.24× |
| Arialys Therapeutics, Inc. | Series A | $29.1M | $49.2M | 3.14× |
| Nuclein, LLC | Series A | $34.5M | $48.3M | 3.09× |
| Phantom Neuro Inc. | Series A | $15.4M | $45.7M | 2.92× |
| Circulate Health, Inc. | Series A | $13.0M | $43.3M | 2.77× |
| Biovantix Biotechnology, Inc | Series A | $15.0M | $42.2M | 2.70× |
| Bariendo Inc. | Series A | $11.1M | $40.9M | 2.61× |
| ENDRA Life Sciences Inc. | Series A | $26.8M | $40.9M | 2.61× |
| Medici Therapeutics, Inc. | Series A | $14.8M | $39.8M | 2.54× |
| Onconetix, Inc. | Series A | $22.0M | $37.7M | 2.41× |
| Mel-Mont Medical, Inc. this company | Series A | $10.2M | $654K | 0.04× |
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| Seed | $3.0M | 2020-10-30 | $15.0M | $111.0M | 90% |
| Series A | $6.9M | 2023-08-25 | $31.4M | $54.7M | 90% |
| Series A | $250K | 2025-12-11 | $1.1M | $654K | 90% |
Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.
| Person | Role | Also runs | Tied since |
|---|---|---|---|
| Michael Torres | — | 4 other | 2023-08 |
| Frank Melendez | — | — | 2020-10 |
| Liliana Montes | — | — | 2020-10 |
| Octavio Gonzalez Paredo | — | — | 2020-10 |
Mel-Mont Medical, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| CrossBridge Bio, Inc. | Biotechnology | Series A | $10.8M | $48.5M | network1 shared operator · same sector · same stage |
| Cba Pharma Inc | Biotechnology | Series A | $10.0M | $3.6M | same sector · same stage |
| GelMEDIX, Inc. | Biotechnology | Series A | $9.9M | $1.6M | same sector · same stage |
| Turnpoint Medical Devices, Inc. | Biotechnology | Series A | $9.6M | $3.6M | same sector · same stage |
| InCellDx, Inc. | Biotechnology | Series A | $9.5M | $2.6M | same sector · same stage |
| Axoft, Inc. | Biotechnology | Series A | $9.3M | $3.1M | same sector · same stage |
| Biostem Technologies | Biotechnology | Series A | $9.2M | $2.2M | same sector · same stage |
| SLAM BioTherapeutics, Inc. | Biotechnology | Series A | $9.2M | $2.6M | same sector · same stage |
Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.
| Company | Sector | Stage | Value · est | Match |
|---|---|---|---|---|
| Mellitus, LLC | Biotechnology | Series A | $101.3M | 86% |
| Bergen Medical Products, Inc. | Biotechnology | Seed | $39.9M | 85% |
| Magnus Medical, Inc. | Biotechnology | Series C | $153.8M | 85% |
| Arsenal Medical, Inc. | Biotechnology | Series A | $217.6M | 84% |
| Medical Nutrition Innovation, Inc. | Biotechnology | Seed | $55.5M | 84% |
| Panorama Medicine, Inc. | Biotechnology | Seed | $65.8M | 84% |
| Mimio Health, Inc | Biotechnology | Seed | $24.9M | 84% |
| Mosaic Biosciences, Inc. | Biotechnology | Series A | $176.4M | 84% |
See where Mel-Mont Medical, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at Mel-Mont Medical, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.